REQUEST A DEMO
Total
USD $0.00
Search more companies

MJ Pharm Co., Ltd. (South Korea)

Main Activities: Pharmaceutical and Medicine Manufacturing | Drugs and Druggists' Sundries Merchant Wholesalers
Full name: MJ Pharm Co., Ltd. Profile Updated: October 23, 2023
Buy our report for this company USD 19.99 Most recent financial data: 2022 Available in: English Download a sample report

MJ Pharm Co., Ltd. is engaged in manufacturing pharmaceutical products and raw materials for medicine. The company offers hexanediol, petanediol, octanediol, decanediol, N-phenyl carbazole (white crystalline powder), N-vinyl carbazole (white crystalline powder), chemical items and raw materials medicines such as acitazanolast, adeforvir dipivoxil, docetaxel, imatinib, montelukast sodium, among others. MJ Pharm Co., Ltd. is based in Suwon, with manufacturing plant in Jecheon and Ansan, Gyeonggi-do Province, South Korea. The company was incorporated in 2001 as Myungin Industry.

Headquarters
111, Hancheon-ro Dongdaemun-gu Seoul
Seoul; Seoul;

Contact Details: Purchase the MJ Pharm Co., Ltd. report to view the information.

Website: http://www.mjpharm.co.kr

Basic Information
Total Employees:
Purchase the MJ Pharm Co., Ltd. report to view the information.
Outstanding Shares:
Purchase the MJ Pharm Co., Ltd. report to view the information.
Registered Capital:
Purchase the MJ Pharm Co., Ltd. report to view the information.
Incorporation Date:
August 22, 1991
Key Executives
Purchase this report to view the information.
Chairman
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after MJ Pharm Co., Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
4.42%
Total operating revenue
4.42%
Operating profit (EBIT)
-15.86%
EBITDA
-15.01%
Net Profit (Loss) for the Period
-53.32%
Total assets
4.12%
Total equity
10.92%
Operating Profit Margin (ROS)
-0.18%
Net Profit Margin
-0.27%
Return on Equity (ROE)
-4.83%
Debt to Equity Ratio
-3.64%
Quick Ratio
-0.01%
Cash Ratio
-0%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?